Abstract
BackgroundTocilizumab (TCZ) is an interleukin-6 receptor inhibitor for treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA) and inadequate response to disease modifying anti-rheumatic drugs (DMARDS) or anti-Tumor...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have